Hemophilia A

Search with Google Search with Bing
Information
Disease name
Hemophilia A
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04091386 Active, not recruiting Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) June 10, 2021 June 30, 2027
NCT04461639 Active, not recruiting Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding May 14, 2021 June 30, 2028
NCT03932201 Active, not recruiting Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A October 21, 2019 March 31, 2027
NCT04644575 Active, not recruiting Phase 3 Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A February 23, 2021 January 15, 2027
NCT05147662 Active, not recruiting Phase 3 A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood March 23, 2022 July 10, 2025
NCT03315455 Active, not recruiting Phase 3 Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants April 26, 2018 May 31, 2025
NCT03938792 Active, not recruiting Phase 3 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B March 9, 2020 June 16, 2025
NCT03588299 Active, not recruiting Phase 1/Phase 2 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle". November 7, 2018 November 30, 2026
NCT06224907 Active, not recruiting Phase 3 Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A December 25, 2023 March 2029
NCT04621916 Active, not recruiting Phase 4 Preventing Inhibitor Recurrence Indefinitely September 21, 2020 April 20, 2025
NCT03061201 Active, not recruiting Phase 2 A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A June 21, 2017 June 25, 2024
NCT04158648 Active, not recruiting Phase 3 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors February 10, 2020 December 30, 2025
NCT02941783 Active, not recruiting Drug Use Investigation of Kovaltry in Hemophilia A Patients November 30, 2016 September 30, 2025
NCT03587116 Active, not recruiting Phase 3 A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) July 26, 2018 July 26, 2024
NCT04370054 Active, not recruiting Phase 3 Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults August 18, 2020 October 25, 2028
NCT03370913 Active, not recruiting Phase 3 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) December 19, 2017 November 2024
NCT02615691 Active, not recruiting Phase 3 A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A November 12, 2015 October 31, 2024
NCT04158934 Active, not recruiting A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A July 9, 2020 February 28, 2030
NCT03370172 Active, not recruiting Phase 1/Phase 2 A Study of BAX 888 in Male Adults With Severe Hemophilia A March 31, 2018 April 24, 2025
NCT04323098 Active, not recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A December 8, 2020 January 2027
NCT04293523 Active, not recruiting A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health March 30, 2020 April 2026
NCT05707351 Active, not recruiting Phase 3 A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A March 27, 2023 October 8, 2024
NCT04073498 Active, not recruiting Phase 1/Phase 2 The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) August 14, 2019 October 2024
NCT03520712 Active, not recruiting Phase 1/Phase 2 Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 April 3, 2018 November 2024
NCT03432520 Active, not recruiting Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A August 14, 2018 December 2032
NCT03154437 Approved for marketing An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
NCT00243659 Completed Phase 3 Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery April 2006 June 2008
NCT00245245 Completed Phase 2 Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII May 2005 June 2007
NCT00279578 Completed N/A Clot Formation and Clot Stability in Patients With Severe Haemophilia A January 2006 June 2006
NCT00284193 Completed Phase 4 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII January 2005 November 2009
NCT00289536 Completed Phase 4 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A February 2, 2006 April 1, 2007
NCT00331006 Completed Phase 2 Rituximab to Treat Severe Hemophilia A June 2006 January 2012
NCT00357656 Completed Phase 4 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery May 29, 2006 December 9, 2015
NCT00375323 Completed Phase 3 Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
NCT00543439 Completed Phase 3 Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII December 2007 April 2018
NCT00581438 Completed Study Evaluating Approach to Treatment of Haemophilia A and B in Spain June 2007 December 2007
NCT00586521 Completed Phase 4 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) February 2006 March 2008
NCT00623480 Completed Phase 3 Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment March 2008 November 2013
NCT00629837 Completed Phase 1 Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 September 2005 March 2006
NCT00632814 Completed Phase 4 Russian Kogenate Pediatric Study June 2007 September 2009
NCT00666406 Completed Phase 4 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A March 31, 2008 February 18, 2009
NCT00717626 Completed Phase 2 Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A July 2008 April 2011
NCT00824798 Completed Gait Evaluation in Haemophiliac Patients January 2009 January 2011
NCT00839202 Completed N/A Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay September 2006 February 2009
NCT00851721 Completed Phase 3 Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor March 31, 2009 October 17, 2012
NCT00864552 Completed International PMS Study - KOGENATE Bayer December 2002 December 2005
NCT00868530 Completed Phase 3 Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects September 2008 December 2009
NCT00874926 Completed EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS June 2008 April 2013
NCT00879541 Completed Phase 2 Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A February 2009 October 2010
NCT00895037 Completed Study Evaluating Pharmacovigilance Of Refacto AF July 17, 2009 October 19, 2016
NCT00914459 Completed Phase 4 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients December 2009 April 2016
NCT00916032 Completed Phase 4 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A June 29, 2009 April 1, 2010
NCT00922597 Completed Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery August 2008 September 2011
NCT00927667 Completed Phase 4 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens June 2009 December 2010
NCT00932555 Completed EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan April 2009 December 2011
NCT00936312 Completed Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study March 2008 August 2011
NCT00936845 Completed Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study April 2005 January 2010
NCT00950170 Completed Phase 4 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting February 10, 2010 November 24, 2016
NCT00952822 Completed Phase 1 Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection August 8, 2008 October 23, 2009
NCT00969319 Completed Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America September 2009 February 2014
NCT00989196 Completed Phase 2 Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A May 2010 September 2012
NCT00994929 Completed Phase 2 Efficacy and Safety of IL-11 in DDAVP Unresponsive January 2010 April 2012
NCT01029340 Completed Phase 3 Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A December 2009 March 2013
NCT01034904 Completed Health Related Quality of Life of Youth and Young Adults With Hemophilia A October 2009 November 2013
NCT01053715 Completed Quality of Life Study of Helixate NexGen January 2010 January 2015
NCT01064284 Completed Phase 4 Survey of Inhibitors in Plasma-Product Exposed Toddlers January 2010 May 2015
NCT01090206 Completed N/A Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia March 2010 March 2015
NCT01159587 Completed Prophylaxis Versus On-demand Therapy Through Economic Report July 2004 December 2010
NCT01184820 Completed Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration October 13, 2010 October 10, 2011
NCT01217255 Completed Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World September 2010 October 2013
NCT01229007 Completed Phase 3 Study of Biostate® in Children With Hemophilia A August 2010 July 2014
NCT01233258 Completed Phase 3 A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A January 2011 December 2012
NCT00000582 Completed Phase 3 Cooperative Study of Factor VIII Inhibitors July 1978 July 1979
NCT01386268 Completed Kogenate FS Regulatory Post-Marketing Surveillance June 2011 August 2013
NCT01439971 Completed Phase 1 Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia December 2011 October 2015
NCT01454739 Completed Phase 3 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A December 2011 October 2017
NCT01458106 Completed Phase 3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A November 2012 December 2013
NCT01477437 Completed N/A Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia November 2011 March 2013
NCT01486927 Completed Phase 2/Phase 3 An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A February 2012 December 2014
NCT01510418 Completed Socialization of Adult Men With Congenital Hemophilia A or B May 2011 December 2013
NCT01568580 Completed Phase 3 Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A December 2004 September 2006
NCT01571934 Completed Inhibitor Development in Patients With Hemophilia A Undergoing Surgery November 2011 March 2016
NCT01579903 Completed Phase 1 Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) August 2012 January 2013
NCT01580293 Completed Phase 2/Phase 3 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A April 23, 2012 November 21, 2019
NCT01589848 Completed Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador March 2013 June 2013
NCT01599819 Completed Phase 1 BAX 855 Dose-Escalation Safety Study September 30, 2011 July 27, 2012
NCT01652027 Completed Hemophilia Inhibitor Previously Untreated Patient Study July 2011 March 2020
NCT01653639 Completed Phase 1 Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 July 2012 December 2012
NCT01736475 Completed Phase 2/Phase 3 Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) January 31, 2013 July 17, 2014
NCT01748201 Completed Phase 4 Viscosupplementation in Patients With Hemophilic Arthropathy November 2012 March 2013
NCT01757405 Completed Phase 3 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen February 20, 2013 November 11, 2014
NCT01775618 Completed Phase 3 Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A May 29, 2013 February 19, 2020
NCT01790828 Completed Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A February 2014 August 2014
NCT01810666 Completed Phase 4 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A March 2013 January 2014
NCT01913405 Completed Phase 3 Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures December 20, 2013 September 23, 2016
NCT01921855 Completed Phase 1 Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors January 2009 December 2009
NCT01945593 Completed Phase 3 BAX 855 Continuation October 15, 2013 March 2, 2018
NCT01959919 Completed Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO January 27, 2014 December 12, 2016
NCT02035605 Completed Phase 1 A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients January 20, 2014 July 20, 2017
NCT02061072 Completed Web-based Application for the Population Pharmacokinetic Service - Phase 1 January 2015 June 2019
NCT02078427 Completed ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) June 28, 2011 January 16, 2024
NCT02093065 Completed Platelet Function in Patients With Hemophilia A March 2015 February 1, 2020
NCT02093741 Completed ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) September 20, 2013 January 20, 2016
NCT02170402 Completed Phase 4 China ADVATE PTP Study June 26, 2014 May 31, 2016
NCT02172950 Completed Phase 3 An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A October 13, 2014 January 19, 2021
NCT02190149 Completed Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS July 22, 2014 March 29, 2016
NCT02199717 Completed An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia September 2013 September 2016
NCT02210091 Completed Phase 3 BAX 855 Pediatric Study October 31, 2014 October 23, 2015
NCT02225483 Completed Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function September 2014 December 2016
NCT02234323 Completed Phase 3 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A January 12, 2015 September 23, 2019
NCT02263066 Completed Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis October 2014 July 2015
NCT02284789 Completed N/A Colorado Adult Joint Assessment Scale (CAJAS) Validation February 2015 October 2015
NCT02319070 Completed 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece January 13, 2015 February 28, 2018
NCT02362581 Completed N/A Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A December 2012 January 2014
NCT02396862 Completed Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment December 9, 2015 March 26, 2018
NCT02418793 Completed Phase 1 A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B May 2015 September 2018
NCT02461992 Completed Phase 1 Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A July 2015 August 2015
NCT02476942 Completed A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment May 26, 2015 March 31, 2017
NCT02483208 Completed Phase 1 Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate June 2015 December 2015
NCT02492984 Completed Phase 4 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A April 2015 August 2016
NCT02506023 Completed Phase 1 Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers July 2015 June 15, 2018
NCT02528968 Completed N/A National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A September 2015 November 30, 2017
NCT02554773 Completed Phase 1/Phase 2 An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B September 18, 2015 March 21, 2023
NCT02571569 Completed Phase 1 A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors October 28, 2015 October 11, 2018
NCT02581969 Completed Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." April 14, 2016 June 21, 2018
NCT02582060 Completed N/A Individualizing Hemophilia Prophylaxis Using Thromboelastography May 20, 2014 December 31, 2017
NCT02585960 Completed Phase 3 BAX 855 PK-guided Dosing November 23, 2015 August 5, 2018
NCT01318707 Completed Biomarkers Serum Collection Methodology Pilot Study December 2010 May 2011
NCT00000705 Completed Phase 1 Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia March 1989
NCT00002276 Completed N/A The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
NCT00002386 Completed Phase 4 Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
NCT00005304 Completed Delta Hepatitis and Liver Disease in Hemophiliacs September 1986 September 1991
NCT00005305 Completed Hepatitis Delta Infections in Hemophiliacs September 1987 September 1991
NCT00005309 Completed Prospective Study of HIV Infection in Hemophiliacs July 1990 March 1995
NCT00005518 Completed Epidemiology and Immunology of Hemophilia A Inhibitors June 1998 August 2003
NCT00007371 Completed Hepatitis C in Clinically Discordant Hemophilic Siblings September 1999 August 2004
NCT00037544 Completed Phase 3 Study Evaluating ReFacto AF in Severe Hemophilia A August 2004
NCT00038909 Completed N/A Study Evaluating ReFacto in Hemophilia A September 1994 May 2001
NCT00038935 Completed Phase 3 Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A February 2003
NCT00092976 Completed Phase 4 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery February 2003 July 2007
NCT00141843 Completed Phase 3 Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A July 2005 November 2006
NCT00157040 Completed Phase 2/Phase 3 Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A June 7, 2002 January 4, 2005
NCT00157053 Completed Phase 2/Phase 3 Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 November 22, 2001 August 3, 2004
NCT00157105 Completed Phase 2/Phase 3 Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery February 12, 2001 August 3, 2004
NCT00157157 Completed Phase 3 Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients April 1, 2004 September 11, 2009
NCT00162019 Completed Phase 3 Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients March 31, 2003 August 24, 2004
NCT00178607 Completed Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia August 2002 October 2015
NCT00189982 Completed Phase 2/Phase 3 Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 December 17, 2004 November 10, 2006
NCT00195442 Completed Study Evaluating Refacto For Pharmacovigilance July 1999 January 2010
NCT00207597 Completed Joint Outcome Study September 1995 August 2005
NCT00212459 Completed N/A The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs May 2005 April 2008
NCT00214734 Completed ADVATE Post Authorization Safety Surveillance October 14, 2004 March 2, 2007
NCT00243386 Completed Phase 4 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A January 4, 2006 June 16, 2010
NCT02622321 Completed Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors November 18, 2015 December 1, 2020
NCT02634723 Completed Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A December 23, 2015 June 30, 2016
NCT02634918 Completed Ultrasonography in Hemophilic Joint Disease and Serum Markers January 2016 December 2019
NCT02674997 Completed GAS-Hem Feasibility Study August 5, 2016 November 2, 2016
NCT02716194 Completed Phase 1 BAX 826 Dose-Escalation Safety Study March 3, 2016 January 17, 2017
NCT02727647 Completed Phase 4 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients May 2015 March 2016
NCT02740413 Completed Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study January 11, 2016 December 31, 2017
NCT02795767 Completed Phase 3 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors July 22, 2016 November 11, 2020
NCT02847637 Completed Phase 3 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors September 27, 2016 May 12, 2022
NCT02851082 Completed N/A Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. April 2016 January 2017
NCT02911233 Completed Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity March 2014 September 2015
NCT02962765 Completed Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ January 2015 August 20, 2020
NCT02971930 Completed Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A June 20, 2017 December 15, 2017
NCT02976753 Completed Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products December 2016 November 3, 2021
NCT03003533 Completed Phase 1/Phase 2 A Gene Transfer Study for Hemophilia A January 26, 2017 December 5, 2023
NCT03006965 Completed Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® November 11, 2016 December 22, 2022
NCT03020160 Completed Phase 3 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A January 30, 2017 June 29, 2022
NCT03103542 Completed Phase 4 Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies August 29, 2017 August 31, 2020
NCT03169972 Completed ADYNOVATE Drug Use-Results Survey April 12, 2017 September 15, 2023
NCT03185897 Completed Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia June 14, 2017 March 17, 2021
NCT03191799 Completed Phase 3 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors September 5, 2017 November 19, 2020
NCT03205163 Completed Phase 1/Phase 2 A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) August 28, 2017 November 12, 2018
NCT03313531 Completed Evaluation of a Standardized Protocol for Thrombin Generation Assay April 15, 2017 January 28, 2019
NCT03364998 Completed Phase 1 BAY94-9027 PK Study Comparing to Another Long Acting Product November 30, 2017 September 28, 2018
NCT03379974 Completed Phase 4 Exercise Versus DDAVP in Patients With Mild Hemophilia A July 31, 2018 December 5, 2019
NCT03380780 Completed Phase 1 A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers March 12, 2018 September 18, 2018
NCT03392974 Completed Phase 3 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg March 14, 2018 June 5, 2023
NCT03405337 Completed Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies February 14, 2018 June 13, 2018
NCT03417102 Completed Phase 3 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors February 14, 2018 June 23, 2021
NCT03417245 Completed Phase 3 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors March 1, 2018 July 14, 2021
NCT03507582 Completed N/A Virtual Reality for Hemophilia April 2016 December 28, 2016
NCT03815318 Completed Phase 3 Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A January 21, 2019 January 16, 2020
NCT03818529 Completed ATHN 8: Previously Untreated Patients (PUPs) Matter Study October 3, 2018 December 31, 2022
NCT03824522 Completed Post Marketing Surveillance Study for ADYNOVATE in South Korea February 25, 2019 January 5, 2024
NCT03834727 Completed Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders September 5, 2018 April 1, 2022
NCT03876301 Completed Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants January 21, 2019 May 2, 2023
NCT03915080 Completed Phase 4 Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A December 2016 April 9, 2021
NCT04015492 Completed Phase 1 Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) August 8, 2019 January 29, 2020
NCT04072237 Completed Phase 1 Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia September 24, 2019 June 17, 2020
NCT04085458 Completed Phase 4 Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) September 23, 2019 August 26, 2022
NCT04131920 Completed Handheld Ultrasound (HHUS) for Home Use in Hemophilia October 1, 2019 June 22, 2022
NCT04133883 Completed N/A Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination January 13, 2020 July 13, 2022
NCT04396639 Completed Phase 4 Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients January 25, 2020 September 24, 2020
NCT04456387 Completed Phase 3 An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. October 15, 2020 September 30, 2021
NCT04560933 Completed A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A August 25, 2020 October 20, 2023
NCT04565236 Completed Phase 4 A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A September 22, 2020 March 15, 2024
NCT04677803 Completed Phase 2 BT200 in Hereditary Bleeding Disorders December 14, 2020 September 10, 2021
NCT04728217 Completed Phase 4 Health Related Quality of Life of Youth and Young Adults With Haemophilia A April 15, 2021 February 20, 2023
NCT04731701 Completed Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) May 5, 2021 July 19, 2022
NCT04759131 Completed Phase 3 Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A February 19, 2021 January 18, 2023
NCT04784988 Completed Phase 4 Intensive Replacement Treatment in Haemophilia Patients With Synovitis March 1, 2022 March 1, 2024
NCT04845399 Completed Phase 3 Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A April 16, 2021 June 26, 2021
NCT04876365 Completed A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate November 30, 2021 February 28, 2022
NCT04941898 Completed A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. June 30, 2021 March 15, 2024
NCT04953000 Completed A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A August 19, 2021 April 4, 2023
NCT04985682 Completed Phase 4 A Study of ADVATE in People With Hemophilia A in India January 14, 2022 February 10, 2023
NCT05042440 Completed Phase 1 Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A August 11, 2021 November 24, 2021
NCT05251090 Completed Phase 1 A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection June 16, 2021 May 9, 2022
NCT05279924 Completed N/A Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast July 1, 2021 October 20, 2022
NCT05449197 Completed Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France July 1, 2022 January 5, 2023
NCT05450640 Completed Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in France January 9, 2023 January 9, 2023
NCT05606640 Completed Gaining Insight Into the Complexity of Pain in Patients With Haemophilia February 13, 2020 October 13, 2023
NCT05752565 Completed N/A Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A January 9, 2020 December 30, 2020
NCT05804734 Completed Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia June 1, 2021 December 31, 2021
NCT06357572 Completed Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem March 26, 2024 March 27, 2024
NCT05768386 Enrolling by invitation A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) January 1, 2023 January 2040
NCT03533504 Enrolling by invitation Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability May 9, 2018 June 30, 2024
NCT03655223 Enrolling by invitation Early Check: Expanded Screening in Newborns October 15, 2018 December 31, 2025
NCT05936580 Not yet recruiting Phase 4 Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery February 2024 December 2025
NCT05636163 Not yet recruiting Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting December 15, 2022 February 20, 2023
NCT06238908 Not yet recruiting Early Phase 1 Safety and Efficacy Study of NGGT003 in Hemophilia A Patients January 31, 2024 January 31, 2030
NCT06014320 Not yet recruiting Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease October 1, 2023 October 1, 2024
NCT05248594 Not yet recruiting Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A August 2024 August 2025
NCT06104826 Not yet recruiting Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab December 2023 December 2025
NCT05980377 Not yet recruiting Patterns of Hemophilia Care in Assiut Children Patients September 1, 2023 August 1, 2024
NCT06297655 Not yet recruiting Phase 3 A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A April 2024 April 2025
NCT05981313 Not yet recruiting Viscoelastic Properties of Lower Extremity Muscles in Patients With Hemophilia August 15, 2023 December 30, 2023
NCT05523128 Not yet recruiting N/A The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients. October 2022 October 2024
NCT05454774 Not yet recruiting Early Phase 1 A Study of FVIII Gene Therapy for Hemophilia A July 15, 2022 September 15, 2027
NCT06369740 Not yet recruiting Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring June 1, 2024 June 4, 2024
NCT06147414 Not yet recruiting Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders April 2024 December 2026
NCT05932914 Not yet recruiting Liver Biopsy Following Gene Therapy For Hemophilia July 2024 May 2025
NCT04418414 Not yet recruiting Phase 1 Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A September 1, 2024 August 2039
NCT05879549 Recruiting N/A Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia November 15, 2023 May 1, 2025
NCT05911763 Recruiting A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A June 30, 2023 June 6, 2028
NCT05754619 Recruiting Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children. October 14, 2022 May 14, 2023
NCT05605678 Recruiting Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) December 9, 2022 November 2024
NCT05580692 Recruiting N/A A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV) March 14, 2023 November 2025
NCT05789524 Recruiting Phase 2 The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B July 6, 2023 June 5, 2026
NCT03615053 Recruiting N/A Personalized Medicine for Canadians With Hemophilia July 24, 2019 September 30, 2023
NCT04472169 Recruiting UPLC-MS/MS Monitoring of Emicizumab Therapy April 13, 2022 February 2024
NCT05687474 Recruiting Baby Detect : Genomic Newborn Screening September 1, 2022 August 31, 2025
NCT05568719 Recruiting Phase 3 Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively December 28, 2022 April 8, 2038
NCT04563520 Recruiting Phase 3 SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis June 2024 September 2025
NCT03327779 Recruiting World Bleeding Disorders Registry January 26, 2018 January 2028
NCT05643560 Recruiting An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A December 29, 2022 June 30, 2027
NCT03947567 Recruiting Phase 4 Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. July 26, 2019 April 1, 2025
NCT04645199 Recruiting National Longitudinal Cohort of Hematological Diseases December 1, 2020 December 1, 2030
NCT04676048 Recruiting Phase 1/Phase 2 ASC618 Gene Therapy in Hemophilia A Patients August 3, 2022 December 2026
NCT05987449 Recruiting Phase 1/Phase 2 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A September 21, 2023 June 16, 2032
NCT04690322 Recruiting Phase 4 POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies April 15, 2021 July 2025
NCT04728841 Recruiting N/A Gene Therapy for Chinese Hemophilia A March 4, 2021 July 31, 2028
NCT06025552 Recruiting Phase 1 Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects August 2, 2023 February 2024
NCT06158334 Recruiting Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) June 1, 2022 December 1, 2024
NCT04805021 Recruiting Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells November 30, 2021 June 30, 2025
NCT05487976 Recruiting Phase 3 Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor April 28, 2022 April 2023
NCT06145373 Recruiting Phase 1 A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab March 1, 2024 May 19, 2028
NCT06297486 Recruiting Phase 3 Study of a Gene Therapy Treatment for Hemophilia A March 13, 2024 September 4, 2035
NCT06111638 Recruiting Phase 1/Phase 2 Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs October 31, 2023 June 30, 2030
NCT06185335 Recruiting Phase 1/Phase 2 A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A July 26, 2023 June 2033
NCT06273865 Recruiting Version Testing of EnzySystem Version A for Hemophilia A May 29, 2024 December 15, 2024
NCT05281718 Recruiting Early Phase 1 Factor IX as Adjunctive Therapy to Emicizumab (EMIX) August 1, 2022 July 2024
NCT06212505 Recruiting EVALUATION OF THE OVERALL HAEMOSTATIC CAPACITY OF MIM8 WITH GLOBAL HAEMOSTASIS ASSAYS AND FIBRIN CLOT ULTRASTRUCTURE March 28, 2024 May 28, 2025
NCT05022459 Recruiting Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis August 16, 2023 January 2028
NCT05036278 Recruiting Phase 4 Prophylaxis Regimen for Hemophilia A Patients July 28, 2022 September 14, 2024
NCT04023019 Recruiting Treatment of Hemophilia A Patients With FVIII Inhibitors March 17, 2020 June 2029
NCT06222697 Recruiting A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A January 24, 2024 June 30, 2026
NCT05145127 Recruiting Phase 3 Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors November 17, 2021 July 31, 2030
NCT05265767 Recruiting Phase 1 Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A April 1, 2022 January 1, 2039
NCT05611801 Recruiting Phase 3 A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B December 9, 2022 September 10, 2028
NCT02912143 Recruiting German Pediatric Hemophilia Research Database January 1, 2017 December 31, 2028
NCT03001830 Recruiting Phase 1/Phase 2 Gene Therapy for Haemophilia A. June 14, 2017 December 2029
NCT03818763 Recruiting Phase 1 Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A April 29, 2020 May 1, 2033
NCT05856903 Recruiting Impact of Emicizumab on Activated Clotting Time Using the i-STAT Alinity Analyzer July 12, 2023 March 2025
NCT06349473 Recruiting Phase 1 A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B) April 15, 2024 March 30, 2026
NCT04131036 Recruiting Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A April 4, 2019 August 2026
NCT00759655 Terminated Phase 3 Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age June 2009 December 2009
NCT01445197 Terminated Phase 3 Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development December 2012 December 2013
NCT01434511 Terminated Phase 3 Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A October 3, 2011 July 29, 2013
NCT05856266 Terminated Phase 4 An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa August 24, 2023 December 6, 2023
NCT01376700 Terminated Phase 3 Early Prophylaxis Immunologic Challenge (EPIC) Study August 26, 2011 November 16, 2012
NCT00995046 Terminated N/A Individually Tailored Prophylaxis in Patients With Severe Hemophilia A September 2009
NCT00947193 Terminated Phase 2 Study of Ataluren (PTC124) in Hemophilia A and B October 14, 2009 August 30, 2011
NCT00884390 Terminated Phase 4 Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings May 2009 March 2013
NCT00765726 Terminated Phase 4 Study Evaluating The Safety Of Xyntha In Usual Care Settings February 2009 August 2011
NCT00623727 Terminated Phase 2 BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A June 2008 October 2010
NCT04541628 Terminated Phase 1/Phase 2 Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A September 28, 2020 October 28, 2022
NCT00621673 Terminated Phase 4 Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A May 2006 October 2006
NCT00306670 Terminated Phase 2/Phase 3 Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A April 2006 August 2011
NCT02634424 Terminated N/A PK Driven Prophylaxis for Hemophilia A November 25, 2015 May 12, 2016
NCT02807753 Terminated The Hemophilia Ultrasound Project September 16, 2016 December 7, 2020
NCT02895945 Terminated Phase 3 BAX 802 in CHA With Inhibitors December 22, 2016 January 22, 2021
NCT00281333 Terminated N/A The Influence of "Karate" on Bleeding in Hemophilic Patients. October 2006
NCT02402829 Terminated A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture November 2014 November 28, 2018
NCT02392156 Terminated Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes July 2015 December 2015
NCT05395858 Terminated A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers January 17, 2023 November 6, 2023
NCT03204539 Terminated Phase 4 INdividualized ITI Based on Fviii(ATE) Protection by VWF June 1, 2017 July 19, 2019
NCT03248141 Terminated Understanding Hemophilia A and B Drug Dosage Administration Patterns September 1, 2017 March 14, 2018
NCT03344003 Terminated Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq June 28, 2018 November 20, 2020
NCT03361137 Terminated Phase 4 Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures June 28, 2018 March 13, 2020
NCT01460147 Terminated N/A Osteoporosis and MRI Study in Hemophilia October 30, 2011 April 13, 2012
NCT03603275 Terminated Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry August 6, 2018 May 14, 2020
NCT01626105 Unknown status Personalized Prediction of Tolerance and Immunogenicity in Hemophilia June 2012 June 2014
NCT03947320 Unknown status Phase 3 Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A. December 20, 2019 September 20, 2020
NCT02282410 Unknown status N/A Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A December 2014 December 2016
NCT05439642 Unknown status N/A Validation and Reliability of the CHO-KLAT in Turkish June 1, 2022 December 1, 2022
NCT04060836 Unknown status Phase 1 Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. May 8, 2019 March 2020
NCT02938156 Unknown status UK - EHL Outcomes Registry December 17, 2016 October 2019
NCT05187936 Unknown status Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy October 1, 2021 December 31, 2022
NCT02930317 Unknown status Phase 3 Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A August 2016 December 2017
NCT02921945 Unknown status Phase 3 Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A October 2016 June 2018
NCT02888223 Unknown status Phase 1 Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A September 2016 July 2017
NCT02750085 Unknown status Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia April 2016 December 2020
NCT04845555 Unknown status Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions September 1, 2019 December 30, 2022
NCT01619046 Unknown status Phase 3 Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A March 2013 September 2015
NCT02622646 Unknown status Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients August 2016 February 2018
NCT03217032 Unknown status Phase 1 Lentiviral FVIII Gene Therapy June 1, 2020 June 1, 2022
NCT03286153 Unknown status N/A Comparison of Ideal vs. Actual Weight Base Factor Dosing January 2017 December 2018
NCT02479087 Unknown status Phase 4 Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients January 2015 January 2020
NCT02280265 Unknown status N/A Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A November 2014 December 2016
NCT04590456 Unknown status N/A Pulsed Electromagentic Field in Haemophilia September 1, 2020 December 19, 2020
NCT03747653 Unknown status A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection March 8, 2019 May 31, 2020
NCT04583930 Unknown status Clinical and Health-related Outcome of rFVIIIFc Prophylaxis February 1, 2021 April 20, 2023
NCT02061033 Unknown status Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease March 2013 December 2018
NCT02027779 Unknown status Phase 3 Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A January 2014 February 2016
NCT04303936 Unknown status N/A PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) January 9, 2020 December 30, 2020
NCT00797381 Unknown status Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia May 2009 May 2011
NCT04061109 Unknown status Phase 3 Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. May 15, 2019 March 2020
NCT02718677 Withdrawn Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis September 1, 2019 January 1, 2022
NCT00151385 Withdrawn Phase 4 Study Evaluating Inhibitor Specificity in Hemophilia A November 2005 October 2007
NCT02726139 Withdrawn Improved Factor VIII Inhibitor Evaluation July 15, 2016 January 25, 2021
NCT04030052 Withdrawn Phase 3 Emicizumab PUPs and Nuwiq ITI Study February 17, 2022 January 19, 2023
NCT01541527 Withdrawn Non Neutralizing Antibodies: Prevalence and Characterization February 2012 August 2013
NCT00168051 Withdrawn Phase 4 Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A April 2005 November 2005
NCT04541875 Withdrawn Medication Adherence and Non-adherence in Adults With Rare Disease January 2021 September 2022
OrphaNumber from OrphaNet (Orphanet)
98878
MeSH unique ID (MeSH (Medical Subject Headings))
D006467